What a fascinating read 
We need multiple EHRs in our ecosystem AND we need sharing of information for interoperability.
Just like competing pharmaceutical companies, it would be nice if arbitration can be done independent of for-profit companies. PHARMAC has served us well, in my opinion, in regards to fair access to medicines. Yes, it would be nice if the PHARMAC budget were bigger and there were more options for new and expensive biological and oncology treatments, but overall, I think the process of PHARMAC is transparent and considerate.
Will Hira be able to play a similar role when considering the issues raised in this legal dispute? With an API meeting Hira standards, would this situation have been avoided?
How will the pending ââprincipalsâ of Transitions of Care & Results Managementâ mentioned by @Anna be helpful: Addressing Correspondence Challenges in Healthcare?
Patients have multiple providers, across settings . . . especially those with lots of complex chronic conditions. We must have multiple EHRs and health IT products to ensure continual innovation. So, this use-case highlights the challenges of interoperability . . . hopefully we have some equity-focused solutions here in Aotearoa